Bank of Montreal Can trimmed its position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 81.2% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 11,012 shares of the medical research company’s stock after selling 47,689 shares during the quarter. Bank of Montreal Can’s holdings in Charles River Laboratories Intl. were worth $1,237,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in CRL. Signaturefd LLC acquired a new position in Charles River Laboratories Intl. in the first quarter valued at approximately $105,000. Adviser Investments LLC acquired a new position in Charles River Laboratories Intl. in the first quarter valued at approximately $152,000. Verition Fund Management LLC acquired a new position in Charles River Laboratories Intl. in the first quarter valued at approximately $245,000. Campbell & CO Investment Adviser LLC acquired a new position in Charles River Laboratories Intl. in the second quarter valued at approximately $270,000. Finally, Gateway Investment Advisers LLC acquired a new position in Charles River Laboratories Intl. in the second quarter valued at approximately $292,000. Hedge funds and other institutional investors own 98.02% of the company’s stock.

CRL stock opened at $121.13 on Friday. The company has a market capitalization of $5.79 billion, a PE ratio of 22.98, a PEG ratio of 1.51 and a beta of 0.66. Charles River Laboratories Intl. Inc has a twelve month low of $96.70 and a twelve month high of $130.66. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.72 and a quick ratio of 1.48.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 8th. The medical research company reported $1.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.46 by $0.16. The business had revenue of $585.30 million during the quarter, compared to the consensus estimate of $570.65 million. Charles River Laboratories Intl. had a return on equity of 25.26% and a net margin of 6.38%. The company’s revenue was up 24.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.29 earnings per share. sell-side analysts predict that Charles River Laboratories Intl. Inc will post 5.9 EPS for the current year.

In related news, COO Davide Molho sold 11,600 shares of the stock in a transaction on Monday, July 23rd. The stock was sold at an average price of $125.00, for a total transaction of $1,450,000.00. Following the completion of the sale, the chief operating officer now directly owns 22,079 shares of the company’s stock, valued at $2,759,875. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director George Massaro sold 300 shares of the stock in a transaction on Monday, June 25th. The stock was sold at an average price of $115.55, for a total value of $34,665.00. Following the sale, the director now directly owns 14,037 shares of the company’s stock, valued at $1,621,975.35. The disclosure for this sale can be found here. Insiders sold 33,258 shares of company stock valued at $4,001,244 over the last three months. Corporate insiders own 2.10% of the company’s stock.

A number of brokerages recently issued reports on CRL. Jefferies Financial Group upped their price target on Charles River Laboratories Intl. from $140.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, August 9th. Barclays upped their price target on Charles River Laboratories Intl. from $110.00 to $120.00 and gave the company an “equal weight” rating in a report on Thursday, August 9th. Bank of America upped their price target on Charles River Laboratories Intl. from $120.00 to $125.00 and gave the company a “buy” rating in a report on Monday, July 16th. Zacks Investment Research raised Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $117.00 price target for the company in a report on Friday, May 11th. Finally, ValuEngine raised Charles River Laboratories Intl. from a “hold” rating to a “buy” rating in a report on Wednesday, July 18th. Six analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $122.00.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: Investing in Dividend Stocks

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.